2. Search Result
Search Result
Results for "

pentylenetetrazol

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1302
    Quinidine hydrochloride monohydrate
    20+ Cited Publications

    		 P-glycoprotein PARP Caspase Apoptosis Potassium Channel Cardiovascular Disease Neurological Disease
    Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures .
    Quinidine hydrochloride monohydrate
  • HY-W127668
    Triethylcholine iodide

    		Acyltransferase Neurological Disease
    Triethylcholine iodide is a choline acetyltransferase inhibitor and a regulator of the acetylcholine synthesis pathway. Triethylcholine iodide inhibits acetylcholine synthesis in brain tissues and blocks neuromuscular and autonomic ganglionic transmission. Triethylcholine iodide exerts weak curare-like effects at extremely high concentrations. Triethylcholine iodide elevates the pentylenetetrazol seizure threshold, alters electroencephalogram patterns in Felis catus, but does not affect the maximal electroshock seizure threshold in Oryctolagus cuniculus. Triethylcholine iodide can be used in seizure-related research .
    Triethylcholine iodide
  • HY-106316
    CGS 20625

    		GABA Receptor Neurological Disease
    CGS 20625 is a potent, selective and orally active partial agonist for the central benzodiazepine receptor. CGS 20625 inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors with an IC50 of 1.3 nM. CGS 20625 enhances GABA in Xenopus laevis oocytes . CGS 20625 can be used for the research of pentylenetetrazol-induced seizures and anxiety .
    CGS 20625
  • HY-Y0729
    4-Chlorocinnamic acid
    1 Publications Verification

    		 Tyrosinase Bacterial Fungal Drug Derivative Infection Neurological Disease
    4-Chlorocinnamic acid is a derivative of Cinnamic acid (HY-N0610A). 4-Chlorocinnamic acid inhibits the monophenolase and diphenolase activities of mushroom tyrosinase with IC50 values of 0.477 mM and 0.229 mM, respectively. 4-Chlorocinnamic acid inhibits the mycelial growth of Colletotrichum gloeosporioides. 4-Chlorocinnamic acid exhibits anticonvulsant activity against acute epilepsy induced by pentylenetetrazol .
    4-Chlorocinnamic acid
  • HY-B1606
    Chlorothymol

    Chlorthymol; 6-Chlorothymol

    		 Environmental Pollutants Bacterial AP-1 GABA Receptor Infection Neurological Disease
    Chlothymol is a potent positive modulator of the GABAA receptor subunit LGC-37, anticonvulsant, and antibacterial agent. Chlothymol inhibits Pentylenetetrazol-induced c-fos expression. Chlothymol inhibits the growth of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) strains, including LAC, with an MIC of 32 μg/mL. Chlorothymol has protective effects against epileptic seizures in various mouse models .
    Chlorothymol
  • HY-170833
    Anticonvulsant agent 8

    		GABA Receptor Neurological Disease
    Anticonvulsant agent 8 (compound D4) is an anticonvulsant agent that inhibits GABAA currents with ED50 values of 2.23 and 24.60 mg/kg in the maximum electroshock (MES) and pentylenetetrazol (PTZ) tests in mouse models, respectively .
    Anticonvulsant agent 8
  • HY-117162
    S 1432

    		Cholinesterase (ChE) Neurological Disease
    S 1432 is a central nervous system depressant with anticonvulsant and muscle relaxant effects. S 1432 significantly reduces acetylcholine levels in the striatum inhibits convulsions induced by pentylenetetrazol. S 1432 can be used in the development of psychotropic drugs .
    S 1432
  • HY-123681
    R 57720

    		Others Neurological Disease
    R 57720 is an antiepileptic agent that exhibits dose-dependent anticonvulsant activity across multiple postnatal rat age groups. R 57720 inhibits severe generalized tonic-clonic seizures induced by Pentylenetetrazol. R 57720 can be used for epilepsy research .
    R 57720
  • HY-172887
    Kv7.2/Kv7.3 activator-2

    		Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC50: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .
    Kv7.2/Kv7.3 activator-2
  • HY-178016
    H3R antagonist 8

    		Histamine Receptor Neurological Disease
    H3R antagonist 8 is a selective nonimidazole histamine H3 receptor antagonist (IC50 = 0.35 μM). H3R antagonist 8 exhibits hERG channel blockade activity (IC50 = 0.67 μM). H3R antagonist 8 inhibits seizures by antagonizing H3 receptor. H3R antagonist 8 reduces tonic hind limb extension (THLE) in mice in the maximal electroshock seizure (MES) model (ED50 = 20.21 mg/kg) and and shortens pentylenetetrazol (PTZ)-induced total movement distance in AB strain zebrafish larvae. H3R antagonist 8 can be used for the study of epilepsy .
    H3R antagonist 8
  • HY-174899
    AMPA-IN-2

    		iGluR Neurological Disease
    AMPA-IN-2 is an orally active AMPA inhibitor that can cross the blood-brain barrier. AMPA-IN-2 improves epileptic seizures by inhibiting the intrinsic excitability of neurons and inhibiting the excitability of glutamatergic transmission. AMPA-IN-2 exerts anti-epileptic effects in the pentylenetetrazol (PTZ) model and can be used as a promising candidates with high broad-spectrum anti-epileptic potential .
    AMPA-IN-2
  • HY-W744266
    9α,10α-Epoxyhexahydrocannabinol

    		Drug Metabolite Neurological Disease
    9α,10α-Epoxyhexahydrocannabinol is an active metabolite of delta 9-tetrahydrocannabinol. 9α,10α-Epoxyhexahydrocannabinol has anti-convulsant activity. 9α,10α-Epoxyhexahydrocannabinol reduces body temperature, prolongs pentobarbital-induced sleep, and exerts anticonvulsant activity against pentylenetetrazol-induced seizures in mice .
    9α,10α-Epoxyhexahydrocannabinol
  • HY-W975902
    MDL-27531

    		Glycine Receptor (GlyR) Neurological Disease
    MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction .
    MDL-27531
  • HY-180056
    CAII-IN-12

    		Carbonic Anhydrase NKCC mTOR Neurological Disease
    CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
    CAII-IN-12
  • HY-W115674
    Quinidine hydrochloride

    		P-glycoprotein PARP Caspase Apoptosis Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Quinidine hydrochloride is an orally active antiarrhythmic agent. Quinidine hydrochloride reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride exerts sustained block and open-channel block effects on IK(f). Quinidine hydrochloride alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride can be used in studies related to uterine sarcoma and seizures .
    Quinidine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: